Introduction
Malaria is an infectious disease caused by parasites belonging to the genus Plasmodium, having five species which infect humans: Plasmodium falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. 1 The main symptoms presented by the disease are fever, chills, headache, vomiting, anemia, diarrhea, anorexia, fatigue. The untreated malaria can evolve to pulmonary edema, renal complications, obstructive jaundice, causing the death of infected individual. 2 According to the World Health Organization (WHO), about three billion people are exposed to the risk of having malaria, of these, 216 million are affected by the disease and 655,000 die from it. In Brazil, the most important species are P. vivax, responsible for 90% of the cases, and P. falciparum, responsible for the most serious cases and for the mortality increase. A major factor contributing to the spread of the disease is the resistance of parasites to current antimalarial drugs used in therapy. 3 In this context, new groups started to develop strategies to search for new antimalarial drugs. Based on molecular biology techniques and high throughtput screening. 4 Although many studies have focused on the screening of new molecules with in vitro and in vivo antimalarial activity, few compounds reached the stage of clinical trials. Therefore, it is of fundamental importance to focus efforts to find new molecules with potential antimalarial activity to create a therapeutic arsenal. 3 A major factor contributing to the spread of the disease is the resistance of parasites to current antimalarial drugs used in therapy. 3 In addition, the plasmodium resistance to commercially available drugs for antimalarial therapy is a threatening factor in controlling the disease worldwide. 5 One strategy used for the development of new drugs is the use of in silico techniques due to high experimental costs such as X-ray crystallography and in vivo biological assay for few molecular targets. Hence, molecular modeling techniques, such as comparative modeling 6 , docking 7 , molecular dynamics 8 and virtual screening 9 , have been used as a tool to development of new drugs. Such techniques allow researchers to build molecular target scaffolds to simulate and predict toxicity, activity, bioavailability and effectiveness. Therefore this rational drug design project, reduces the time and the costs to develop a new drug, wherein, virtual screening approaches, consists in the identification of novel molecules against specific molecular targets. 10 It has been largely used to obtain the pharmacoforic conformation and the binding energy, of a set of compounds against a biological receptor.
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In this context, our research group has studied specific targets building a database denoted by Our Own Molecular Targets (OOMT) 12 with 40 structures from Protein Data Bank (PDB) 13 and built by comparative homology modeling. 6 In a previous study, we performed virtual screening process on 10 compounds using OOMT database. Following, the compound I showed specificity for the malaria targets. Hence, this compound was addressed for antimalarial assay. As a result of experimental work, the compound I had a satisfactory antimalarial activity. In this study, we described a success case of a hit compound obtained from virtual High Throughput Screening (vHTS). This process consisted the use of docking approach between the compound I and specific P. falciparum molecular targets, such as plasmepsin IV, plasmepsin II, falcipaina II14 and PfATP6. 15 All these proteins are present in the digestive vacuole of P. falciparum, except PfATP6 present in membrane. Additionally, the digestive vacuole enzymes work with optimum pH of 4-5. 16 
Methods
The previous results of virtual screening using OOMT database motivated us to study new molecular targets against selected P. falciparum targets. The molecular targets plasmepsin IV plasmepsin II, falcipain II, which were obtained from PDB under codes 2ANL, 1LF3, 3BPF, respectively; 13 while PfATP6 was obtained by previous comparative modeling methodology. 15 The promising compound was designed in MarvinSketch program where its protonation was adjusted to pH 4.5. Next, it was refined in the MOPAC17 program using the semi-empirical parametric method 7 (PM7). 18 The compound was oriented toward the binding site through a grid box with dimensions of 20 Å covering all binding site. The coordinates X, Y and Z were defined according to table 1 with spaced points of 1 Å centered in the ligand. Following, crystallographic ligands were re-docked into the targets to evaluate the docking methodology, obtaining the root mean square deviation (RMSD) values for heavy atoms. Two distinct approaches were used, rigid and flexible docking using programa AutoDock Vina7. After the rigid docking, the binding site amino acid residues were chosen for flexible docking (table 2) .
In addition, the targets state of protonation was adjusted to acid pH using PROPKA from Maestro software 19 . All docking simulations were carried using AutoDock vina 7 Table1. Grid box size and position for all molecular targets. ASP34  ILE14  GLN36  ILE251   GLY36  MET15  CYS42  LEU253   ILE75  ILE32  TRP43  PHE254   TYR77  ASP34  LEU72  GLN257   GLY78  GLY36  ASN81  LEU258   LEU131  TYR77  GLY82  ILE261   ASP214  VAL78  GLY83  ILE748   THR217  SER79  LEU84  ILE752   VAL292  ILE123  HIS174  ASN 755   ILE300  TYR192  ILE756   ASP214  VAL759   SER218  PHE763   LEU815   ILE816   LEU821   TYR824 ILE825 
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Results and discussion
Initially, the re-docking using AutoDock Vina process showed that the crystallographic and docked ligand shared the same conformation into the binding site. values found after crystallographic ligands were re-docked into the targets to evaluate the docking methodology
These results evaluated the docking methodology considering the RMSD value less 2.0 Å. In this context, the AutoDock Vina program showed the best RMSD results compared with SwissDock and DockThor softwares7.
The AutoDock Vina 7 , DockThor 20 and SwissDock21 software were used to generate the binding energy of compound for four enzymes. Table 4 shows the binding energies between the promise ligand and all targets for rigid and flexible approach. As can be seen, the Autodock Vina program obtained more accuracy results than other softwares. In addition, both rigid and flexible approaches through AutoDock Vina suggested the 3BPF and PfATP6 as molecular targets for compound I.
The compound could perform electrostatic, van der Waals and Pi interaction. Fig. 1 shows the interaction of compound with 3BPF3 and PfATP6 into the binding site. The crystallographic ligand and compound shared the same amino acids in the binding site Fig.2 .
In addition, the compound was evaluated against Lipinski rule (logP < 5, number of hydrogen bond groups acceptors (HBA) < 10, number of hydrogen bonds groups donors (HBD) (<5 and MW < 500) 22 using Data Warrior software. 
Conclusions
This work evaluated the accuracy among three different docking methodologies, which AutoDock Vina showed more suitable results for our system.
The data addressed PfATP6 and falcipain II as a potential molecular target for this synthetic compound. In addition, this compound fits into Lipinski rule with acceptable values of Log S and druglikeness, suggestion it as a potentianl new antimalarial drug. Noteworthy, after docking studies, this compound was addressed to antimalarial assay. As a result, this compound was able to kill 78% of parasites in vitro test. Further ligand optimization cycle had begun generating new hit for docking and biological assay.
